Acurx Pharmaceuticals Shares Pull Back After 107.93% Rally
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 12 2026
0mins
Should l Buy ACXP?
Source: Benzinga
- Price Pullback: Acurx Pharmaceuticals shares fell 12.95% to $5.24 in premarket trading on Thursday after a significant 107.93% rally on Wednesday, indicating market caution regarding its short-term performance.
- Clinical Trial Update: The company announced a new trial for ibezapolstat targeting recurrent C. difficile infection, citing a 96% clinical cure rate from Phase 2 data, which lays a solid foundation for future market performance.
- Financial Outlook: Acurx is set to report its fourth-quarter 2025 earnings on Friday, with an estimated loss per share of $1.00, an improvement from a $3.40 loss per share a year earlier, reflecting gradual financial recovery.
- Technical Analysis: While ACXP is trading 162.5% above its 20-day SMA and 48.3% above its 100-day SMA, the stock has declined 35.16% over the past 12 months, indicating that the long-term trend still requires repair, with key support at $5.00.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ACXP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ACXP
Wall Street analysts forecast ACXP stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.760
Low
30.00
Averages
30.50
High
31.00
Current: 3.760
Low
30.00
Averages
30.50
High
31.00
About ACXP
Acurx Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. It develops antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its research and development (R&D) pipeline include antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile (C. difficile), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug-resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Its lead antibiotic candidate, ibezapolstat targets the pol IIIC enzyme.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Acurx Secures New Patent to Strengthen IP Portfolio
- Patent Protection Expansion: Acurx Pharmaceuticals has secured a new patent from the Korean Intellectual Property Office covering DNA Polymerase IIIC inhibitors, further strengthening its intellectual property portfolio, having already obtained four U.S. patents and patents in Israel, Japan, India, Australia, and Korea, indicating a robust global IP strategy.
- Clinical Trial Readiness: Acurx's lead product candidate, ibezapolstat, is ready to advance to international Phase 3 pivotal registration trials for oral treatment of acute Clostridioides difficile infection, marking a significant milestone in antibiotic development that could transform treatment paradigms.
- Innovative Drug Development: The company is initiating a groundbreaking clinical trial for multiply-recurrent CDI, which has the potential to shift treatment from two agents to one, showcasing the innovative potential and competitive edge of its research pipeline.
- Broad Market Prospects: Acurx's R&D pipeline focuses on developing new classes of small molecule antibiotics for difficult-to-treat bacterial infections, particularly targeting drug-resistant bacteria, which is expected to create significant market opportunities amid increasing antibiotic demand.
See More
Acurx Secures New Patent to Strengthen IP Portfolio
- Patent Protection Expansion: Acurx has secured a new patent from the Korean Intellectual Property Office covering DNA Polymerase IIIC inhibitors, further strengthening its intellectual property portfolio, having already obtained four U.S. patents and patents in Israel, Japan, India, Australia, and Korea, indicating a robust global IP strategy.
- Clinical Trial Readiness: Acurx's lead product candidate, ibezapolstat, is ready to advance to international Phase 3 pivotal registration trials for oral treatment of acute C. difficile infection, marking a significant milestone in antibiotic development that could transform treatment paradigms.
- Innovative R&D Platform: The company is developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, leveraging an AI-supported drug discovery platform, which is expected to create a transformational shift in the treatment of serious infections, particularly against MRSA and other resistant strains.
- Significant Market Potential: Acurx's R&D pipeline includes antibiotic candidates targeting various life-threatening bacteria, especially Bacillus anthracis, a Category A bioterrorism threat, highlighting its strategic importance in public health and potential for future market recognition.
See More
Acurx Pharmaceuticals Q4 2025 Earnings Call Highlights
- Funding Progress: Acurx Pharmaceuticals secured $1.4 million in gross proceeds from the execution of Series F Warrants in October 2025, enhancing liquidity to support upcoming clinical trials and operational needs.
- Clinical Trial Launch: The company plans to initiate a new open-label pilot trial for recurrent CDI in the second half of 2026, with full enrollment expected within 12 to 15 months and projected costs between $4 million to $5 million, indicating a proactive approach in clinical development.
- R&D Expense Reduction: Research and development expenses for Q4 2025 were reported at $0.3 million, down 62.5% from $0.8 million in Q4 2024, reflecting effective cost control measures, while total annual R&D expenses decreased from $5.4 million to $1.8 million, showcasing improved financial health.
- FDA Regulatory Dynamics: Management highlighted the FDA's potential shift to a one-trial registration requirement, which, if formalized, could accelerate the approval timeline for ibezapolstat, enhancing the company's competitive position and market entry speed.
See More
Acurx Pharmaceuticals Reports Q4 Loss, Shares Drop
- Financial Loss: Acurx Pharmaceuticals reported a net loss of $0.73 per diluted share for Q4 2025, which, while better than the expected $1.65 loss, indicates ongoing financial challenges that may affect investor confidence.
- Cash Position: The company ended the quarter with $7.6 million in cash, up from $3.7 million a year earlier, suggesting improved financing efforts, yet ongoing operational losses remain a concern.
- Clinical Trial Progress: Acurx is preparing for international Phase 3 clinical trials for its lead antibiotic candidate, Ibezapolstat, aimed at treating C. difficile infections, which is crucial in addressing the rising global antibiotic resistance issue.
- Future Outlook: Acurx is set to provide its next financial update on May 12, 2026, with analysts estimating an improved EPS loss of $1.24, reflecting cautious optimism about the company's future developments.
See More
Acurx Pharmaceuticals Reports 2025 Financial Highlights
- Improved Cash Position: As of December 31, 2025, Acurx's cash balance reached $7.6 million, a significant increase from $3.7 million in 2024, indicating progress in financing that supports ongoing R&D activities.
- Significant Reduction in R&D Expenses: R&D expenses for Q4 2025 were $0.3 million, down from $0.8 million in Q4 2024, primarily due to lower manufacturing and consulting costs, reflecting effective cost control measures by the company.
- Decreased Net Loss: The net loss for Q4 2025 was $1.6 million, or $0.73 per share, an improvement from a $2.8 million loss and $3.29 per share in Q4 2024, indicating positive changes in the company's financial health.
- Clinical Trial Readiness: Acurx's lead antibiotic candidate, Ibezapolstat, is set to enter international Phase 3 clinical trials, having received positive regulatory guidance from the EMA, which, if successful, will facilitate its marketing authorization application in Europe, highlighting its strategic importance.
See More
Acurx Pharmaceuticals Reports 2025 Financial Results and Clinical Advances
- Funding Progress: In October 2025, Acurx raised approximately $1.4 million through the exercise of 170,068 Series F Warrants, enhancing cash flow to support ongoing R&D projects and operational stability.
- Research Collaboration Outcomes: In November 2025, results from Acurx's collaboration with Leiden University Medical Center were published in Nature Communications, revealing the target structure of the DNA polymerase IIIC inhibitor ibezapolstat for the first time, establishing a strong foundation for the development of new antibiotics and showcasing the company's research capabilities.
- Clinical Trial Launch: On March 9, 2026, Acurx announced the initiation of a groundbreaking clinical trial for ibezapolstat in patients with recurrent CDI, aiming to shift treatment paradigms from two agents to one, which could position the company as a leader in this therapeutic area if successful.
- Improved Financial Position: As of December 31, 2025, Acurx reported a cash balance of $7.6 million, a significant increase from $3.7 million in 2024, with reductions in R&D and administrative expenses indicating effective cost management and financial health.
See More
Acurx Secures New Patent to Strengthen IP Portfolio
- Patent Protection Expansion: Acurx Pharmaceuticals has secured a new patent from the Korean Intellectual Property Office covering DNA Polymerase IIIC inhibitors, further strengthening its intellectual property portfolio, having already obtained four U.S. patents and patents in Israel, Japan, India, Australia, and Korea, indicating a robust global IP strategy.
- Clinical Trial Readiness: Acurx's lead product candidate, ibezapolstat, is ready to advance to international Phase 3 pivotal registration trials for oral treatment of acute Clostridioides difficile infection, marking a significant milestone in antibiotic development that could transform treatment paradigms.
- Innovative Drug Development: The company is initiating a groundbreaking clinical trial for multiply-recurrent CDI, which has the potential to shift treatment from two agents to one, showcasing the innovative potential and competitive edge of its research pipeline.
- Broad Market Prospects: Acurx's R&D pipeline focuses on developing new classes of small molecule antibiotics for difficult-to-treat bacterial infections, particularly targeting drug-resistant bacteria, which is expected to create significant market opportunities amid increasing antibiotic demand.
See More
Acurx Secures New Patent to Strengthen IP Portfolio
- Patent Protection Expansion: Acurx has secured a new patent from the Korean Intellectual Property Office covering DNA Polymerase IIIC inhibitors, further strengthening its intellectual property portfolio, having already obtained four U.S. patents and patents in Israel, Japan, India, Australia, and Korea, indicating a robust global IP strategy.
- Clinical Trial Readiness: Acurx's lead product candidate, ibezapolstat, is ready to advance to international Phase 3 pivotal registration trials for oral treatment of acute C. difficile infection, marking a significant milestone in antibiotic development that could transform treatment paradigms.
- Innovative R&D Platform: The company is developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, leveraging an AI-supported drug discovery platform, which is expected to create a transformational shift in the treatment of serious infections, particularly against MRSA and other resistant strains.
- Significant Market Potential: Acurx's R&D pipeline includes antibiotic candidates targeting various life-threatening bacteria, especially Bacillus anthracis, a Category A bioterrorism threat, highlighting its strategic importance in public health and potential for future market recognition.
See More
Acurx Pharmaceuticals Q4 2025 Earnings Call Highlights
- Funding Progress: Acurx Pharmaceuticals secured $1.4 million in gross proceeds from the execution of Series F Warrants in October 2025, enhancing liquidity to support upcoming clinical trials and operational needs.
- Clinical Trial Launch: The company plans to initiate a new open-label pilot trial for recurrent CDI in the second half of 2026, with full enrollment expected within 12 to 15 months and projected costs between $4 million to $5 million, indicating a proactive approach in clinical development.
- R&D Expense Reduction: Research and development expenses for Q4 2025 were reported at $0.3 million, down 62.5% from $0.8 million in Q4 2024, reflecting effective cost control measures, while total annual R&D expenses decreased from $5.4 million to $1.8 million, showcasing improved financial health.
- FDA Regulatory Dynamics: Management highlighted the FDA's potential shift to a one-trial registration requirement, which, if formalized, could accelerate the approval timeline for ibezapolstat, enhancing the company's competitive position and market entry speed.
See More
Acurx Pharmaceuticals Reports Q4 Loss, Shares Drop
- Financial Loss: Acurx Pharmaceuticals reported a net loss of $0.73 per diluted share for Q4 2025, which, while better than the expected $1.65 loss, indicates ongoing financial challenges that may affect investor confidence.
- Cash Position: The company ended the quarter with $7.6 million in cash, up from $3.7 million a year earlier, suggesting improved financing efforts, yet ongoing operational losses remain a concern.
- Clinical Trial Progress: Acurx is preparing for international Phase 3 clinical trials for its lead antibiotic candidate, Ibezapolstat, aimed at treating C. difficile infections, which is crucial in addressing the rising global antibiotic resistance issue.
- Future Outlook: Acurx is set to provide its next financial update on May 12, 2026, with analysts estimating an improved EPS loss of $1.24, reflecting cautious optimism about the company's future developments.
See More
Acurx Pharmaceuticals Reports 2025 Financial Highlights
- Improved Cash Position: As of December 31, 2025, Acurx's cash balance reached $7.6 million, a significant increase from $3.7 million in 2024, indicating progress in financing that supports ongoing R&D activities.
- Significant Reduction in R&D Expenses: R&D expenses for Q4 2025 were $0.3 million, down from $0.8 million in Q4 2024, primarily due to lower manufacturing and consulting costs, reflecting effective cost control measures by the company.
- Decreased Net Loss: The net loss for Q4 2025 was $1.6 million, or $0.73 per share, an improvement from a $2.8 million loss and $3.29 per share in Q4 2024, indicating positive changes in the company's financial health.
- Clinical Trial Readiness: Acurx's lead antibiotic candidate, Ibezapolstat, is set to enter international Phase 3 clinical trials, having received positive regulatory guidance from the EMA, which, if successful, will facilitate its marketing authorization application in Europe, highlighting its strategic importance.
See More
Acurx Pharmaceuticals Reports 2025 Financial Results and Clinical Advances
- Funding Progress: In October 2025, Acurx raised approximately $1.4 million through the exercise of 170,068 Series F Warrants, enhancing cash flow to support ongoing R&D projects and operational stability.
- Research Collaboration Outcomes: In November 2025, results from Acurx's collaboration with Leiden University Medical Center were published in Nature Communications, revealing the target structure of the DNA polymerase IIIC inhibitor ibezapolstat for the first time, establishing a strong foundation for the development of new antibiotics and showcasing the company's research capabilities.
- Clinical Trial Launch: On March 9, 2026, Acurx announced the initiation of a groundbreaking clinical trial for ibezapolstat in patients with recurrent CDI, aiming to shift treatment paradigms from two agents to one, which could position the company as a leader in this therapeutic area if successful.
- Improved Financial Position: As of December 31, 2025, Acurx reported a cash balance of $7.6 million, a significant increase from $3.7 million in 2024, with reductions in R&D and administrative expenses indicating effective cost management and financial health.
See More
